DCGI nod for India-made COVID-19 vaccine 'Covaxin' human trials

Clay Curtis
June 30, 2020

Phase one trials are small-scale, usually involving few participants, to assess whether the vaccine is safe for humans.

No vaccine has yet been approved for commercial use against the illness caused by the new coronavirus, but over a dozen vaccines from more than 100 candidates globally are being tested in humans.

The country's "first" indigenous COVID-19 vaccine COVAXIN, developed by city-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), has got the nod for human clinical trials from the Drug Controller General of India (DGCI), the company said on Monday.

Last week, the World Health Organization said the experimental vaccine AstraZeneca vaccine was probably the leading candidate and most advanced in terms of development, Reuters reported.

A vaccine would see potential profits for the medical and science industry, makers of medicine and researchers.

Covid-19 pandemic not even close to being over
On Monday a state of emergency was declared in the capital Brasilia, following a surge there. Non-essential shops will close from Tuesday and, as will schools from Thursday.

"We are proud to announce "Covaxin", India's first indigenous vaccine against COVID-19". Another four or five home-grown vaccines are in early stages of development.

Pune-based Serum Institute of India, the world's largest vaccine maker by number of doses produced and sold globally, has also partnered to mass produce a vaccine being developed by the University of Oxford and backed by the United Kingdom government.

Coronavirus infection has already cost over 16,475 lives in India and the world is now waiting with bated breath for a vaccine.

Correspondents say a vaccine would normally take years, if not decades, to develop. "Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India's strength in handling the future pandemics", Ella added.

"J&J has a long-standing commitment to address global health crisis and will continue to work closely with partners worldwide to combat the current COVID-19 pandemic through a multi-pronged approach.We will continue to bring our full resources and best scientific minds to combat this pandemic", Mr Stoffels said.

Other reports by

Discuss This Article